PR91797

GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire=KYODO JBN/ --

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and

commercializing next-generation vaccines for serious infectious diseases, today

announced that John J. Trizzino, Executive Vice President, Chief Commercial

Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on

September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is

taking place September 21-23 via livestream as part of its coverage of the 76th

meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19

vaccine candidate, NVX-CoV2373, will be a topic of discussion along with

fostering global vaccine access.

Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

Interview details are as follows:

Date:             Tuesday, September 21, 2021

Time:             8:50 - 9:05 a.m.

Location:   Livestream ( https://pages.devex.com/devex-at-unga-76.html )

Title:             Fireside chat: A status report on the COVID-19 vaccine rollout

Novavax panelist: John J. Trizzino, Executive Vice President, Chief Commercial

Officer and Chief Business Officer

Moderator:  Jenny Lei Ravelo, Senior Reporter, Devex

For more information or to register for the fireside chat, visit:

https://pages.devex.com/devex-at-unga-76.html

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved

health globally through the discovery, development and commercialization of

innovative vaccines to prevent serious infectious diseases. The company's

proprietary recombinant technology platform combines the power and speed of

genetic engineering to efficiently produce highly immunogenic nanoparticles

designed to address urgent global health needs. Novavax is conducting

late-stage clinical trials for NVX-CoV2373, its vaccine candidate against

SARS-CoV-2, the virus that causes COVID-19. NanoFlu(TM), its quadrivalent

influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase

3 clinical trial in older adults and will be advanced for regulatory

submission. Both vaccine candidates incorporate Novavax' proprietary

saponin-based Matrix-M(TM) adjuvant to enhance the immune response and

stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter (

https://c212.net/c/link/?t=0&l=en&o=3296663-1&h=851843593&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3284297-1%26h%3D2201380132%26u%3Dhttps%253A%252F%252Ftwitter.com%252Fnovavax%26a%3DTwitter&a=Twitter

) and LinkedIn (

https://c212.net/c/link/?t=0&l=en&o=3296663-1&h=925224691&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3284297-1%26h%3D833923221%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fnovavax%26a%3DLinkedIn&a=LinkedIn

).

Contacts:    

Investors

Novavax, Inc.

Erika Schultz | +1 240-268-2022

ir@novavax.com

Solebury Trout

Alexandra Roy | +1 617-221-9197

aroy@soleburytrout.com

Media

Alison Chartan | +1 240-720-7804

Laura Keenan | +1 202-709-7521

media@novavax.com

SOURCE: Novavax, Inc.